[Federal Register Volume 75, Number 173 (Wednesday, September 8, 2010)]
[Notices]
[Pages 54593-54594]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-22377]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket 52-2010]


Foreign-Trade Zone 272--Lehigh Valley, Pennsylvania, Application 
for Subzone, Piramal Critical Care, Inc. (Inhalation Anesthetics 
Manufacturing and Distribution), Bethlehem, Pennsylvania

    An application has been submitted to the Foreign-Trade Zones Board 
(the Board) by the Lehigh Valley Economic

[[Page 54594]]

Development Corporation (LVEDC), grantee of FTZ 272, requesting 
special-purpose subzone status for the inhalation anesthetics 
manufacturing facilities of Piramal Critical Care, Inc. (Piramal), 
located in Bethlehem, Pennsylvania. The application was submitted 
pursuant to the provisions of the Foreign-Trade Zones Act, as amended 
(19 U.S.C. 81a-81u), and the regulations of the Board (15 CFR part 
400). It was formally filed on August 31, 2010.
    The Piramal facilities (95 employees, 445 metric ton capacity) 
consist of 2 sites on 4.3 acres: Site 1 (4.0 acres) is located at 3950 
Sheldon Circle, Bethlehem; and Site 2 (0.3 acres) is located at 2550 
Brodhead Road, Bethlehem. The facilities are used for the manufacture 
and distribution of inhalation anesthetics Sevoflurane and Isoflurane. 
Components and materials sourced from abroad (representing 23% of the 
value of the finished product) include: Hexafluoroisopropyl Methyl 
Ether (HFMOP) and Trifluoroethanol (TFE) (duty rate of 5.5%). The 
application also requests authority to include a limited secondary 
scope of inputs and finished pharmaceutical products that Piramal may 
produce under FTZ procedures in the future. New major activity 
involving these inputs/products would require review by the FTZ Board.
    FTZ procedures could exempt Piramal from customs duty payments on 
the foreign components used in export production. The company 
anticipates that some 40 percent of the plant's shipments will be 
exported. On its domestic sales, Piramal would be able to choose the 
duty rates during customs entry procedures that apply to Sevoflurane 
and Isoflurane (duty free) for the foreign inputs noted above. FTZ 
designation would further allow Piramal to realize logistical benefits 
through the use of weekly customs entry procedures. Customs duties also 
could possibly be deferred or reduced on foreign status production 
equipment. The request indicates that the savings from FTZ procedures 
would help improve the plant's international competitiveness.
    In accordance with the Board's regulations, Maureen Hinman of the 
FTZ Staff is designated examiner to evaluate and analyze the facts and 
information presented in the application and case record and to report 
findings and recommendations to the Board.
    Public comment is invited from interested parties. Submissions 
(original and 3 copies) shall be addressed to the Board's Executive 
Secretary at the address below. The closing period for their receipt is 
November 8, 2010. Rebuttal comments in response to material submitted 
during the foregoing period may be submitted during the subsequent 15-
day period to November 22, 2010.
    A copy of the application will be available for public inspection 
at the Office of the Executive Secretary, Foreign-Trade Zones Board, 
Room 2111, U.S. Department of Commerce, 1401 Constitution Avenue, NW, 
Washington, DC 20230-0002, and in the ``Reading Room'' section of the 
Board's website, which is accessible via www.trade.gov/ftz.
    For further information, contact Maureen Hinman at 
[email protected] or (202) 482-0627.

    Dated: August 31, 2010.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2010-22377 Filed 9-7-10; 8:45 am]
BILLING CODE 3510-DS-S